Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Operating Leases (2019 - 2025)

BeOne Medicines (BEIGF) has disclosed Operating Leases for 7 consecutive years, with $73.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 19.05% to $73.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.6 million through Dec 2025, up 19.05% year-over-year, with the annual reading at $73.6 million for FY2025, 19.05% up from the prior year.
  • Operating Leases for Q4 2025 was $73.6 million at BeOne Medicines, up from $51.4 million in the prior quarter.
  • The five-year high for Operating Leases was $73.6 million in Q4 2025, with the low at $17.7 million in Q1 2024.
  • Average Operating Leases over 5 years is $40.3 million, with a median of $37.3 million recorded in 2021.
  • The sharpest move saw Operating Leases crashed 62.0% in 2023, then surged 209.76% in 2025.
  • Over 5 years, Operating Leases stood at $43.0 million in 2021, then skyrocketed by 36.05% to $58.6 million in 2022, then plummeted by 62.0% to $22.3 million in 2023, then soared by 177.98% to $61.9 million in 2024, then increased by 19.05% to $73.6 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $73.6 million, $51.4 million, and $53.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.